NCT03789331

Brief Summary

This study evaluates the anogenital distance measurement differences between transgender male individuals and normal healthy female individuals. Half of the participants will be selected from the men with a masculine gender identity who were assigned female sex at birth (Woman who wanted to be a man). Transgender men will be evaluated with the vaginal examination, and anogenital distance will be measured at the time of gynecological medico-legal evaluation before the sex reassignment surgery. While the other half of the participants will be selected from healthy female individuals, ordinary healthy women will be selected from patients who come to the gynecology clinic for another reason (Women with normal sexual orientation).

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
150

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Apr 2019

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 26, 2018

Completed
2 days until next milestone

First Posted

Study publicly available on registry

December 28, 2018

Completed
3 months until next milestone

Study Start

First participant enrolled

April 1, 2019

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 15, 2020

Completed
29 days until next milestone

Study Completion

Last participant's last visit for all outcomes

March 15, 2020

Completed
Last Updated

April 2, 2019

Status Verified

March 1, 2019

Enrollment Period

11 months

First QC Date

December 26, 2018

Last Update Submit

March 31, 2019

Conditions

Keywords

transgender malesanogenital distance

Outcome Measures

Primary Outcomes (2)

  • Anogenital Distance (Anus-Clitoris)

    Anogenital Distance (Anus-Clitoris) will be measured from the anterior clitoral surface to the centre of the anus with a digital caliper in centimeters.

    1 hour

  • Anogenital Distance (Anus-Posterior Fourchette)

    Anogenital Distance (Anus-Posterior Fourchette) will be measured from the posterior fourchette to the centre of the anus with a digital caliper in centimeters.

    1 hour

Secondary Outcomes (2)

  • Anti-Mullerian Hormone (AMH) level measurement

    8 hours

  • FSH (Follicle-stimulating hormone), LH (Luteinizing hormone), Estradiol, and Testosteron level measurements

    8 hours

Study Arms (2)

Transgender Male individuals

* Group Description: This group consists of transgender male individuals who come to the gynecology clinic for medico-legal evaluation before the sex reassignment surgery. * Intervention: Anogenital distance measurement with a digital caliper in centimeters in the lithotomy position.

Other: Anogenital distance measurement

Normal healthy female individuals

* Group Description: Healthy women with normal sexual orientation. * Intervention: (The same) Anogenital distance measurement with a digital caliper in centimeters in the lithotomy position.

Other: Anogenital distance measurement

Interventions

The women were kindly asked to lay down in the lithotomy position with their thighs at 45° to the examination table. A digital caliper (Mitutoyo 500-752-10 ABSOLUTE Digimatic Coolant Proof Caliper 0-150mm / 0-6", Mitutoyo Corporation, Japan) was used to measure anogenital distance. Anogenital distance anus to clitoris: will be measured in centimeters from the anterior clitoral surface to the center of the anus. Anogenital distance anus to fourchette: will be measured in centimeters from the posterior fourchette to the center of the anus. Two investigators who were blind to the gynecological status of the women will measure each distance three times, and the mean value of the six measurements of each anogenital distance will be used.

Normal healthy female individualsTransgender Male individuals

Eligibility Criteria

Age18 Years - 50 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

The study population will be healthy transgender male individuals whose gender identity (Male) are different from their birth-assigned sex (Female). These individuals are healthy biologically female persons and want to change their gender to male status. In Turkey, if a woman wants to change her gender, she has to bring a lawsuit against the birth registration office to change her gender to male status. Medico-legal assessments then have to be made at a tertiary gynecological center through the court. The participants will be invited to the study at the time of medico-legal evaluation before the sex reassignment surgery.

You may qualify if:

  • Individuals who are 18-50 years old.
  • Healthy transgender male individuals whose gender identity (Male) are different from their birth-assigned sex (Female). The participants will be invited to the study at the time of medico-legal evaluation before the sex reassignment surgery.

You may not qualify if:

  • Individuals who are older than 50 (People older than 50 cannot change their gender legally in Turkey).
  • Other sexual orientation disorders. (Lesbian, Gay, Bisexual, Queer, Intersex, or Asexual persons)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Uludag University Hospital, Department of Obstetrics and Gynecology

Bursa, Ozluce, 16059, Turkey (Türkiye)

RECRUITING

Related Publications (2)

  • Wu Y, Zhong G, Chen S, Zheng C, Liao D, Xie M. Polycystic ovary syndrome is associated with anogenital distance, a marker of prenatal androgen exposure. Hum Reprod. 2017 Apr 1;32(4):937-943. doi: 10.1093/humrep/dex042.

    PMID: 28333243BACKGROUND
  • Sanchez-Ferrer ML, Mendiola J, Hernandez-Penalver AI, Corbalan-Biyang S, Carmona-Barnosi A, Prieto-Sanchez MT, Nieto A, Torres-Cantero AM. Presence of polycystic ovary syndrome is associated with longer anogenital distance in adult Mediterranean women. Hum Reprod. 2017 Nov 1;32(11):2315-2323. doi: 10.1093/humrep/dex274.

    PMID: 29025054BACKGROUND

Study Officials

  • Adnan Orhan, M.D.

    Uludag University, Department of Obstetrics and Gynecology

    STUDY DIRECTOR

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Obstetrician and Gynecologist (M.D. and researcher)

Study Record Dates

First Submitted

December 26, 2018

First Posted

December 28, 2018

Study Start

April 1, 2019

Primary Completion

February 15, 2020

Study Completion

March 15, 2020

Last Updated

April 2, 2019

Record last verified: 2019-03

Data Sharing

IPD Sharing
Will share

De-identified individual participant data for all primary and secondary outcome measures will be made available.

Shared Documents
STUDY PROTOCOL, ICF
Time Frame
Data will be available within 9 months of study completion.
Access Criteria
Data access requests will be reviewed by an external independent review panel. Requestors will be required to sign a data access agreement.

Locations